Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by Keskinäinen Eläkevakuutusyhtiö Ilmarinen increased on 21 June 2023 above five (5) per cent of Orion Corporation’s total voting rights.
Total positions of Keskinäinen Eläkevakuutusyhtiö Ilmarinen subject to notification:
| % of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 2.68% of shares 5.00% of voting rights | 0.00 | 2.68% of shares 5.00% of voting rights | 141,134,278 shares 776,919,536 voting rights |
| Position of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014369 | 1,847,000 shares 36,940,000 voting rights | 0.00 | 1.31% of shares 4.75% of voting rights | 0.00 |
| FI0009014377 | 1,929,629 shares 1,929,629 voting rights | 0.00 | 1.37% of shares 0.25% of voting rights | 0.00 |
| POINT A SUBTOTAL | 3,776,629 shares 38,869,629 voting rights | 2.68% of shares 5.00% of voting rights | ||
Point B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| POINT B SUBTOTAL |
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
